Selinexor

塞利尼索

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameSelinexor
Drug Alias NameSelinexorum塞立奈索SelinissoXpovioNexpovio +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExportin-1 protein inhibitors
TargetsExportin-1 protein
Therapy Area/IndicationsBone metastasesCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[63] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/03
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKaryopharm Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteShanghai Pharmaceutical Co LtdAntengene Corp Ltd +[19] 
Inactive CompaniesUtah State UniversityUniversity Of California San FranciscoUniversity of Texas Southwestern Medical Center +[14] 
Active IndicationsSolid tumoursPrimary MyelofibrosisThrombocytopenia +[28] 
Inactive IndicationsBone metastasesCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[35] 

Other Information

ATC CodeL01XX66
Related LinksWikipediaDrugBankKEGG